Table 3.
Kaplan-Meier analysis of GRFS at 1 year and adjusted GRFS for adults (≥21 years old)
| Frequency | Survival estimate | Log rank | ||||
|---|---|---|---|---|---|---|
| Factor | Strata | n | Events | Estimate | CI 95% | P value |
| Total | 687 | 525 | 24% | 20-27 | ||
| Conditioning* | MA | 285 | 229 | 21% | 17-25 | .29 |
| RIC | 402 | 296 | 26% | 22-30 | ||
| Stem cell source* | Marrow-matched sibling | 10 | 6 | 48% | 19-77 | .39 |
| PBSC-matched sibling | 260 | 214 | 19% | 15-23 | ||
| Marrow-/PBSC-matched URD | 60 | 45 | 28% | 17-39 | ||
| UCB (single) | 40 | 28 | 32% | 18-46 | ||
| UCB (double) | 317 | 232 | 25% | 21-29 | ||
| Gender | Male | 398 | 306 | 23% | 19-27 | .67 |
| Female | 289 | 219 | 24% | 19-29 | ||
| Diagnosis | ALL | 109 | 87 | 20% | 13-28 | .07 |
| AML | 284 | 206 | 27% | 22-33 | ||
| MDS/MPN/CML | 159 | 127 | 20% | 14-27 | ||
| NHL/Hodgkin/CLL | 90 | 65 | 28% | 19-37 | ||
| Other malignancies | 45 | 40 | 11% | 4-22 | ||
| Disease risk* | Standard risk | 412 | 302 | 27% | 23-31 | .02 |
| High risk | 275 | 223 | 19% | 15-24 | ||
| CMV serostatus | Negative | 297 | 221 | 26% | 21-31 | .22 |
| Positive | 390 | 304 | 22% | 18-26 | ||
| Prior auto-HCT | No | 639 | 492 | 23% | 20-26 | .27 |
| Yes | 48 | 33 | 31% | 19-44 | ||
| Year of HCT* | 2000-2007 | 422 | 342 | 20% | 16-24 | <.01 |
| 2008-2012 | 265 | 183 | 30% | 25-30 | ||
*
Denotes adjusted variable.